Applications

1606 – Request to amend existing MBS Item No 73341 (Fluorescence in situ hybridisation test of tumour tissue from a patient with locally advanced or metastatic non-small cell lung cancer) to add brigatinib

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

Amendment to MBS item.

Service or technology in this application

Anaplastic lymphoma kinase (ALK) Fluorescence in situ hybridisation (FISH) testing identifies tumours that carry the ALK rearrangement obtained from patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), which is of non-squamous histology or histology not otherwise specified. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for brigatinib for the treatment of patients with the ALK rearrangement.

Type: Investigative

Medical condition this application addresses

ALK-positive locally advanced or metastatic NSCLC, which is of non-squamous histology or histology not otherwise specified.

Application documents

Public summary document

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 28 to 29 November 2019